| Literature DB >> 32420333 |
Wei Wang1,2, Xiangyao Sun1,2, Tongtong Zhang1,2,3, Siyuan Sun4, Chao Kong1,2, Shibao Lu1,2.
Abstract
The treatment effects of topping-off technique were still controversial. This study compared all available data on postoperative clinical and radiographic outcomes of topping-off technique and posterior lumbar interbody fusion (PLIF). PubMed, EMBASE, and Cochrane were systematically reviewed. Variations included radiographical adjacent segment disease (RASD), clinical adjacent segment disease (CASD), global lumbar lordosis (GLL), visual analogue scale (VAS) of back (VAS-B) and leg (VAS-L), Oswestry disability index (ODI), Japanese Orthopaedic Association (JOA) score, duration of surgery, estimated blood loss (EBL), reoperation rates, and complication rates. Sixteen studies, including 1372 cases, were selected for the analysis. Rates of proximal RASD (P=0.0004), distal RASD (P=0.03), postoperative VAS-B (P=0.0001), postoperative VAS-L (P=0.02), EBL (P=0.007), and duration of surgery (P=0.02) were significantly lower in topping-off group than those in PLIF group. Postoperative ODI after 3 years (P=0.04) in the topping-off group was significantly less than that in the PLIF group. There was no significant difference in the rates of CASD (P=0.06), postoperative GLL (P=0.14), postoperative ODI within 3 years (P=0.24), and postoperative JOA (P=0.70) and in reoperation rates (P=0.32) and complication rates (P=0.27) between topping-off group and PLIF. The results confirmed that topping-off technique could effectively prevent ASDs after lumbar internal fixation. However, this effect is effective in preventing RASD. Topping-off technique is more effective in improving the subjective feelings of patients rather than objective motor functions compared with PLIF. With the development of surgical techniques, both topping-off technique and PLIF are safe.Entities:
Mesh:
Year: 2020 PMID: 32420333 PMCID: PMC7201464 DOI: 10.1155/2020/2953128
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flow chart showing identification and selection of cases.
Characteristics of included studies.
| Study | Year | Country | Study type | Quality (NOS) | LoE | Device | Patients (F/M) | Age (years) | Follow-up (months) | Segments | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLIF | Topping-off | PLIF | Topping-off | |||||||||
| Putzier et al. [ | 2010 | Germany | Pro | 7 | II | Dynesys | 30 (16/14) | 30 (13/17) | 44.6 | 44.9 | 76.4 | 1 |
| Kaner et al. [ | 2010 | Turkey | Pro | 6 | II | Coflex | 20 | 26 | — | — | 40 | — |
| Liu et al. [ | 2012 | China | Retro | 7 | III | Coflex | 48 (20/28) | 31 (11/20) | 41.5 | 44.6 | 24 | 1 |
| Lee et al. [ | 2013 | Korea | Retro | 7 | III | DIAM | 50 (20/30) | 25 (10/25) | 65.9 ± 8.5 | 65.4 ± 8.7 | 46.8 | 1 |
| Lee et al. [ | 2015 | Korea | Retro | 8 | III | DTO/Nflex | 10 (5/5) | 15 (11/4) | 63.9 ± 7.8 | 60.7 ± 8.3 | 48 | 2 |
| Zhu et al. [ | 2015 | China | Retro | 6 | III | Wallis | 23 (12/11) | 22 (8/14) | 40 | 44.5 | 24 | 1 |
| Lu et al. [ | 2015 | China (Taiwan) | Retro | 7 | III | DIAM | 42 (14/28) | 49 (16/33) | 64.5 ± 7.2 | 59.1 ± 8.6 | 41.5 | 2–4 |
| Li and Wu [ | 2015 | China | Pro | 7 | III | Coflex | 30 (11/19) | 30 (12/18) | 46.4 | 47.3 | 20 (12–42) | 1 |
| Chen et al. [ | 2016 | China | Retro | 7 | III | Coflex | 88 (34/54) | 76 (28/48) | 58.31 ± 4.6 | 57.34 ± 5.1 | 47.2 | 1 |
| Aygun et al. [ | 2017 | Turkey | Retro | 6 | III | Cosmic | 59 (34/25) | 42 (19/23) | 54.2 ± 5.11 | 52 ± 6.02 | 79 | 1–5 |
| Wang et al. [ | 2017 | China | Retro | 7 | III | K-rod | 34 (15/19) | 26 (12/14) | 44.9 | 46.7 | 17.1 | 2 |
| Chen et al. [ | 2017 | China | Retro | 8 | III | Coflex | 68 (26/42) | 60 (22/38) | 56.2 ± 4.2 | 54.2 ± 4.1 | 50 | 2 |
| Cao et al. [ | 2017 | China | Retro | 6 | III | Coflex | 59 (25/34) | 48 (22/26) | 39.3 | 38 | 30 | 1 |
| Li et al. [ | 2017 | China | Retro | 6 | III | Coflex | 54 (29/25) | 45 (22/21) | 63.7 | 61.5 | 35.2 | 1–2 |
| Dobran et al. [ | 2018 | Italy | Retro | 5 | III | NFlex | 12 | 9 | 63 | 66 | 78 | 1–2 |
| Herren et al. [ | 2018 | Germany | RCT | 9 | I | Dynesys | 14 (8/6) | 15 (6/9) | 61.78 (34–76) | 60.9 (47–80) | 37.68 (1.38–72) | 1–5 |
| Li et al. [ | 2019 | China | Retro | 6 | III | Coflex | 54 (29/25) | 45 (24/21) | 53.5 (46–59) | 65.7 (60–75) | 56.4 ± 105.6 (36–37) | 2 |
Notice: NOS = Newcastle–Ottawa Scale score; RCT = randomized controlled trial; Retro = retrospective cohort study; Pro = prospective cohort study; PLIF = posterior lumbar interbody fusion.
Figure 2Forest plot of proximal RASD.
Figure 3Forest plot of CASD.
Figure 4Forest plot of postoperative GLL.
Figure 5Forest plot of postoperative VAS-B.
Figure 6Forest plot of postoperative VAS-L.
Figure 7Forest plot of postoperative ODI within 3 years.
Figure 8Forest plot of postoperative ODI after 3 years.
Figure 9Forest plot of EBL.
Figure 10Forest plot of duration of surgery.
Figure 11Forest plot of complication rates.
Figure 12Forest plot of reoperation rates.